• About us
• Contact

Advertisement

Organisation › Details

Gyroscope Therapeutics Ltd.

Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. Our lead investigational gene therapy, GT005, is currently being evaluated in Phase II clinical trials for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of blindness. GT005 has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of people with GA. Supported by leading life sciences investors, Gyroscope has built a global organisation combining discovery, research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London with locations in Philadelphia and San Francisco, our mission is to preserve sight and fight the devastating impact of blindness. *

 

	Start	2016-08-01 existent
	Group	Novartis (Group)
	Industry	Orbit™ subretinal delivery system
	Person	Farooq, Khurem (Aiolos Bio 202301– CEO + Co-Founder before Gyroscope Therapeutics + Genentech)
	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	11-12 Northdown Street Northdown House
	City	N1 9BN London
	Tel	+44-1438-906770
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Gyroscope Therapeutics Ltd.. (3/26/21). "Press Release: Gyroscope Therapeutics Announces $148 Million Raised in Series C Financing". London.
		Record changed: 2023-07-10

Advertisement

More documents for Novartis (Group)

• [1] FundaMental Pharma GmbH. (4/11/24). "Press Release: FundaMental Pharma Appoints Dr. Dirk Beher as Chief Executive Officer". Heidelberg....
• [2] Novartis AG. (9/11/23). "Press Release: Sandoz Announces Exclusive Deal to Commercialize Biosimilar Ustekinumab". Basel....
• [3] Intellegens Ltd.. (8/30/23). "Press Release: Intellegens and CPI Awarded £1.6m Innovate UK Grant to Advance Manufacture of Oligonucleotide Therapeutics with Machine Learning". Cambridge....
• [4] BioGeneration Ventures B.V.. (7/19/23). "Press Release: Dr. Markus Kalousek and Dr. Andrew Lightfoot Join BGV as Venture Partners". Amsterdam....
• [5] Bicycle Therapeutics plc. (3/28/23). "Press Release: Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates". Cambridge & Boston, MA....
• [6] BioIndustry Assocation (BIA). (1/25/23). "Press Release: BIA Announces New Appointments to the BIA Board"....
• [7] Novartis AG. (9/1/22). "Press Release: Novartis Appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., Steps Down from the Executive Committee of Novartis". Basel....
• [8] Epsilogen Ltd.. (3/2/22). "Press Release: Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing". London....
• [9] Rentschler Biopharma SE. (2/3/22). "Press Release: Rentschler Biopharma further Strengthens Company Leadership Team". Laupheim....
• [10] Novartis AG. (12/22/21). "Press Release: Novartis to Acquire Gyroscope Therapeutics, Adding a One-time Gene Therapy that Could Transform Care for Geographic Atrophy, a Leading Cause of Blindness". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.